NEW YORK, April 3, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on EARS, ANTH, ARLZ, and PETX which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com navigates the Biotech space, which broadly segments into the Medical and Agricultural
Auris Medical Holding
Zug, Switzerland headquartered Auris Medical Holding AG's shares closed Monday's trading session flat at $1.60. The stock recorded a trading volume of 106,267 shares. The Company's shares are trading 45.77% below their 50-day moving average. Additionally, shares of Auris Medical, which focuses on the development of novel products for the treatment of inner ear disorders, have a Relative Strength Index (RSI) of 34.06. Get the full research report on EARS for free by clicking below at:
On Monday, shares in Hayward, California headquartered Anthera Pharmaceuticals Inc. recorded a trading volume of 1.35 million shares. The stock dropped 1.88%, ending the day at $0.31. The Company's shares are trading below their 50-day moving average by 78.89%. Furthermore, shares of Anthera Pharma, which focuses on the development and commercialization of medicines for patients with unmet medical needs, have an RSI of 25.23. ANTH's complimentary research coverage is a few simple steps away at:
Milton, Canada headquartered Aralez Pharmaceuticals Inc.'s stock finished the day 6.00% lower at $1.41 with a total trading volume of 313,270 shares. Shares of the Company, which operates as a specialty pharmaceutical company in Canada, Ireland, and the US, are trading below their 200-day moving average by 9.22%. The stock has an RSI of 35.11.
On March 13th, 2018, Aralez Pharma announced its financial results Q4 and year ended December 31st, 2017. For Q4 2017, total revenues were $28.0 million; SG&A expenses totaled $28.8 million; and net loss was $45.8 million. For the full year, total revenues were $105.9 million, SG&A expenses totaled $116.6 million, and net loss was $125,205 million. Register for your free research report on ARLZ at:
Shares in Leawood, Kansas headquartered Aratana Therapeutics Inc. ended yesterday's session 0.91% higher at $4.45. The stock recorded a trading volume of 565,097 shares, which was above its three months average volume of 499,750 shares. The Company's shares have advanced 14.10% in the last month. The stock is trading 3.42% above its 50-day moving average. Moreover, shares of Aratana Therapeutics, which focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the US and Belgium, have an RSI of 57.25.
On March 13th, 2018, Aratana Therapeutics announced its Q4 and full-year 2017 financial results. For Q4 2017, total net revenues were $10.4 million, and net loss was $15.6 million. For the full year 2017, total net revenues were $25.6 million, and net loss was $47.5 million. As of December 31st, 2017, the Company had approximately $68.0 million in cash, cash equivalents, restricted cash, and short-term investments.
On March 27th, 2018, research firm Stifel upgraded the Company's stock rating from 'Hold' to 'Buy', with a target price of $8 per share. Wall St. Equities' downloadable research report on PETX available at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/this-mornings-technical-outlook-on-biotech-stocks----auris-medical-anthera-pharma-aralez-pharma-and-aratana-therapeutics-300623226.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Lazy eye or amblyopia occurs when sight in one eye is less than the other in early childhood due to ...
Tracheal or windpipe cancer is a rare cancer and its cause is unclear. The most common squamous ...
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...View All